We have now:
2 P2,
1 P1,
3 pivotal trials (the three cancer tests) over or about to be with results to be published at 1h2015 and revenue expected to commence at year end, to a primary market of ~ 50 million per year and expended use of up to 2.5 billion per year.
One cooperation with Teva, one with GM.
GM cooperation: GM identified a problem: approved drugs are found toxic, in particular, cancer drugs show heart toxicity post marketing. This is Hugh loss makers for big Pharma.
So, they are going to build devices using heart stem cells to test drugs on human heart cells lines directly instead of on dogs or rabbits, which seem to vary wildly in their tox response. Their microscopes can analyze huge amount of information and can show exactly what's wrong with the compounds tox. E.g it kills the mitochondria, ruining the cell battery, or it increases the amount of calcium.
They tested it (blind) on approved drugs that were later found toxic, and claim to have gotten 100% correlation with what was found, post marketing. Said machines can so analyze about 900 compounds per day, increasing approval rate and return on drug investment. For the future they have some Science fiction ideas involving machines and bodies or machines making tissues or organs.
There's a dilution coming but in view of the fact we are very close to some sort of revenues and the fact that any one of the actual stem cell clinical trials can be expanded over and over again into further indications I am guardedly optimistic.
From all the SC companies I know, they have to most comprehensive IP, most options open to them, and I dare say, the best management. There is a lot coming in the next 1.5 year.
One negative, CEO west himself is not yet hugely invested. His bosses are. I would like to see when he himself decides the best return on his money is in the company he manages.
Still very early. But major progress had been made on many fronts, not single bet anywhere.
I can't say that for any of the SC companies I follow,
